Results

1–10 of 54 results for RVO

Branch Retinal Vein Occlusion with Retinal Neovascularization
Retina Image Bank: Images of the Week
2025
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Retinal Arteriovenous Malformation
Korey Starkey
Retina Image Bank: Images of the Week
2025
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024
A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Retinal Vein and Artery Occlusions
Aleksandra V. Rachitskaya, MD, FASRS
Updates from the Field
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update
Glenn C. Yiu, MD, PhD
Updates from the Field
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024